MX2022000069A - Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas. - Google Patents
Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas.Info
- Publication number
- MX2022000069A MX2022000069A MX2022000069A MX2022000069A MX2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A
- Authority
- MX
- Mexico
- Prior art keywords
- diazaspiro
- octane
- oxo
- amino
- hidroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865826P | 2019-06-24 | 2019-06-24 | |
| PCT/US2020/039163 WO2020263847A1 (en) | 2019-06-24 | 2020-06-23 | Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000069A true MX2022000069A (es) | 2022-05-24 |
Family
ID=74060350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000069A MX2022000069A (es) | 2019-06-24 | 2020-06-23 | Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas. |
| MX2025002579A MX2025002579A (es) | 2019-06-24 | 2022-01-03 | Formas solidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il)-1-oxo-2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y metodos para prepararlas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002579A MX2025002579A (es) | 2019-06-24 | 2022-01-03 | Formas solidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il)-1-oxo-2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y metodos para prepararlas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220267341A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986399A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7617043B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260061467A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114364380A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020304001B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026380A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3144600A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289198A (cg-RX-API-DMAC7.html) |
| MA (1) | MA56550A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022000069A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020263847A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI887245B (zh) * | 2019-06-24 | 2025-06-21 | 美商諾雷克斯股份有限公司 | 用於產生二氮雜螺內醯胺化合物之方法及中間物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| ES2416354T3 (es) * | 2005-06-21 | 2013-07-31 | Ajinomoto Co., Inc. | Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo |
| MX2011003015A (es) * | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| JP6419087B2 (ja) * | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系nmda受容体モジュレーターおよびその使用 |
| CA2898861C (en) * | 2013-01-29 | 2021-07-20 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| TWI738748B (zh) * | 2016-03-28 | 2021-09-11 | 日商武田藥品工業有限公司 | 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形 |
| PE20190174A1 (es) * | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| TWI887245B (zh) * | 2019-06-24 | 2025-06-21 | 美商諾雷克斯股份有限公司 | 用於產生二氮雜螺內醯胺化合物之方法及中間物 |
-
2020
- 2020-06-23 BR BR112021026380A patent/BR112021026380A2/pt unknown
- 2020-06-23 EP EP20832010.1A patent/EP3986399A4/en active Pending
- 2020-06-23 JP JP2021576883A patent/JP7617043B2/ja active Active
- 2020-06-23 MA MA056550A patent/MA56550A/fr unknown
- 2020-06-23 US US17/621,907 patent/US20220267341A1/en active Pending
- 2020-06-23 KR KR1020267012575A patent/KR20260061467A/ko active Pending
- 2020-06-23 CN CN202080059974.0A patent/CN114364380A/zh active Pending
- 2020-06-23 MX MX2022000069A patent/MX2022000069A/es unknown
- 2020-06-23 WO PCT/US2020/039163 patent/WO2020263847A1/en not_active Ceased
- 2020-06-23 AU AU2020304001A patent/AU2020304001B2/en active Active
- 2020-06-23 KR KR1020227002351A patent/KR102958083B1/ko active Active
- 2020-06-23 CA CA3144600A patent/CA3144600A1/en active Pending
-
2021
- 2021-12-21 IL IL289198A patent/IL289198A/en unknown
-
2022
- 2022-01-03 MX MX2025002579A patent/MX2025002579A/es unknown
-
2025
- 2025-01-06 JP JP2025001914A patent/JP7858096B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114364380A (zh) | 2022-04-15 |
| JP2022539342A (ja) | 2022-09-08 |
| WO2020263847A1 (en) | 2020-12-30 |
| MX2025002579A (es) | 2025-04-02 |
| US20220267341A1 (en) | 2022-08-25 |
| MA56550A (fr) | 2022-04-27 |
| EP3986399A4 (en) | 2023-06-07 |
| AU2020304001A1 (en) | 2022-01-27 |
| EP3986399A1 (en) | 2022-04-27 |
| JP7617043B2 (ja) | 2025-01-17 |
| CA3144600A1 (en) | 2020-12-30 |
| AU2020304001B2 (en) | 2026-04-09 |
| IL289198A (en) | 2022-02-01 |
| KR20260061467A (ko) | 2026-05-06 |
| KR20220061088A (ko) | 2022-05-12 |
| JP7858096B2 (ja) | 2026-05-13 |
| BR112021026380A2 (pt) | 2022-05-10 |
| JP2025069143A (ja) | 2025-04-30 |
| KR102958083B1 (ko) | 2026-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4512399A3 (en) | Solid state forms of tafamidis and salts thereof | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2020001598A (es) | Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5). | |
| MY201832A (en) | Sulfonamide compounds and use thereof | |
| MA40236A (fr) | Formes cristallines de (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanpyrido[1',2':4,5]pyrazino 2,1-b][1,3]oxazépine-10-carboxamide | |
| CL2012002355A1 (es) | Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih. | |
| MX2019004611A (es) | Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas. | |
| ZA202005325B (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| NZ721952A (en) | Delayed release compositions of linaclotide | |
| BR112015032736A2 (pt) | inibidores de bromodomínio cristalino | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
| BR112018071831A2 (pt) | composições anti-irritantes sinérgicas de taurina e aloé e métodos | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| EP4327880A3 (en) | Solid state form of ribociclib succinate | |
| UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
| EA201490222A1 (ru) | Комбинированные составы на основе дарунавира | |
| WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
| MX382609B (es) | Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración. | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| SA520420261B1 (ar) | تركيبات إرنوماب واستخداماتها | |
| UA113540C2 (xx) | Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду | |
| BR112014031706A8 (pt) | Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol |